A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC).
Ho Yeong Lim
Consultant or Advisory Role - Bayer (U)
Chia-Jui Yen
No relevant relationships to disclose
Won-Young Tak
No relevant relationships to disclose
Jeong Heo
No relevant relationships to disclose
Hye Jin Choi
No relevant relationships to disclose
Cheng-Yao Lin
No relevant relationships to disclose
Jung-Hwan Yoon
No relevant relationships to disclose
Chiun Hsu
No relevant relationships to disclose
Kun-Ming Rau
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Winnie Yeo
No relevant relationships to disclose
Joong-Won Park
Consultant or Advisory Role - Advisory Board Member
Honoraria - Symposium Presentation
Miah Hiang Tay
No relevant relationships to disclose
Wen Son Hsieh
No relevant relationships to disclose
Christian Kappeler
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Prabhu Rajagopalan
Employment or Leadership Position - Bayer
Heiko Krissel
Employment or Leadership Position - Bayer
Stock Ownership - Bayer